Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

394 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Digital adherence technologies to improve tuberculosis treatment outcomes in China: a cluster-randomised superiority trial.
Liu X, Thompson J, Dong H, Sweeney S, Li X, Yuan Y, Wang X, He W, Thomas B, Xu C, Hu D, Vassall A, Huan S, Zhang H, Jiang S, Fielding K, Zhao Y. Liu X, et al. Among authors: fielding k. Lancet Glob Health. 2023 May;11(5):e693-e703. doi: 10.1016/S2214-109X(23)00068-2. Lancet Glob Health. 2023. PMID: 37061308 Free PMC article. Clinical Trial.
Effectiveness of a community-based approach for the investigation and management of children with household tuberculosis contact in Cameroon and Uganda: a cluster-randomised trial.
Bonnet M, Vasiliu A, Tchounga BK, Cuer B, Fielding K, Ssekyanzi B, Tchakounte Youngui B, Cohn J, Dodd PJ, Tiendrebeogo G, Tchendjou P, Simo L, Okello RF, Kuate Kuate A, Turyahabwe S, Atwine D, Graham SM, Casenghi M; CONTACT study group. Bonnet M, et al. Among authors: fielding k. Lancet Glob Health. 2023 Dec;11(12):e1911-e1921. doi: 10.1016/S2214-109X(23)00430-8. Epub 2023 Oct 30. Lancet Glob Health. 2023. PMID: 37918417 Free article. Clinical Trial.
Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial.
Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, Moodliar R, Dodd M, Solodovnikova V, Liverko I, Rajaram S, Rassool M, McHugh T, Spigelman M, Moore DA, Ritmeijer K, du Cros P, Fielding K; TB-PRACTECAL team. Nyang'wa BT, et al. Among authors: fielding k. Lancet Respir Med. 2024 Feb;12(2):117-128. doi: 10.1016/S2213-2600(23)00389-2. Epub 2023 Nov 16. Lancet Respir Med. 2024. PMID: 37980911 Free article. Clinical Trial.
Putting technology to the test in tuberculosis care.
Subbaraman R, Fielding K. Subbaraman R, et al. Among authors: fielding k. Lancet. 2024 Mar 9;403(10430):878-879. doi: 10.1016/S0140-6736(24)00412-4. Lancet. 2024. PMID: 38460978 No abstract available.
Acceptability of using the medication monitor and experience of a differentiated care approach for TB treatment adherence among people living with TB in South Africa.
Mukora R, Ahumah B, Maraba N, Orrell C, Jennings L, Naidoo P, Fielding KL, Velen K, Charalambous S, Chetty-Makkan CM. Mukora R, et al. Among authors: fielding kl. PLOS Glob Public Health. 2023 Oct 27;3(10):e0001885. doi: 10.1371/journal.pgph.0001885. eCollection 2023. PLOS Glob Public Health. 2023. PMID: 37889875 Free PMC article.
Four-Month High-Dose Rifampicin Regimens for Pulmonary Tuberculosis.
Jindani A, Atwine D, Grint D, Bah B, Adams J, Ticona ER, Shrestha B, Agizew T, Hamid S, Jamil B, Byamukama A, Kananura K, Mugisha Taremwa I, Bonnet M, Camara LM, Bah-Sow OY, Bah KS, Bah NM, Sow M, Ticona Huaroto CE, Mugruza Pineda R, Tandukar B, Raya BB, Shrestha N, Mathoma A, Mathebula-Modongo UP, Basotli J, Irfan M, Begum D, Muzammil A, Ahmed I, Hasan R, Burgos MV, Sultan F, Hassan M, Masood I, Robb C, Decker J, Grubnic S, Butcher PD, Witney A, Dhillon J, Munshi T, Fielding K, Harrison TS. Jindani A, et al. Among authors: fielding k. NEJM Evid. 2023 Sep;2(9):EVIDoa2300054. doi: 10.1056/EVIDoa2300054. Epub 2023 Aug 22. NEJM Evid. 2023. PMID: 38320155 Clinical Trial.
394 results